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Background: Neuroinflammation and oxidative stress has been shown to be associated with the development of
Parkinson disease (PD). In the present study, we investigated the effect of intraperitoneal (i.p.) administration of
silymarin, on 6-OHDA-induced motor-impairment, brain lipid per-oxidation and cerebrospinal fluid (CSF) levels of
inflammatory cytokine in the rats.
Results: The results showed that silymarin is able to improve motor coordination significantly (p < 0.001) in a dose
dependent manner. There was a significant (p < 0.001) increase in MDA levels of 6-OHDA-lesioned rats whereas; in
silymarin (100, 200 and 300 mg/kg, i.p. for 5 days) pre-treated hemi-parkinsonian rats MDA levels was decreased
markedly (p < 0.001). Furthermore the CSF levels of IL-1β was decreased (p < 0.001) in silymarin (100, 200 and
300 mg/kg) pre-treated rats up to the range of normal non-parkinsonian animals.
Conclusion: We found that pre-treatment with silymarin could improve 6-OHDA-induced motor imbalance by
attenuating brain lipid per-oxidation as well as CSF level of IL-1β as a pro-inflammatory cytokine. We suggest a
potential prophylactic effect for silymarin in PD. However, further clinical trial studies should be carried out to prove
this hypothesis.
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Parkinson’s disease (PD) is the second most common
and progressive neurodegenerative disorder worldwide
with a prevalence of approximately 1% in people over
age 60. Clinically, the disease is characterized by resting
tremor, rigidity, bradykinesia and postural instability
[1-3]. Progression of these symptoms is secondary to the
selective loss of dopaminergic (DA) neurons in the sub-
stantia nigra pars compacta (SNpc) [4]. The primary
cause of PD is still unknown although aging appears to
be a major risk factor. Indeed, mitochondrial impairment
and elevated oxidative stress have been linked to the PD
pathogenesis [5]. It is well agreed that chronic neuro-
inflammation has part in the pathogenesis of the disease* Correspondence: nayebia@tbzmed.ac.ir
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unless otherwise stated.[6,7]. For the first time in 1988, McGeer et al. reported
increase of activated microglia in the SNc of parkinson-
ian patients, which was showed the involving of neuroin-
flammation in PD [8]. Chronic neuro-inflammation
causes to damage of neural cells through generation of
reactive oxygen species (ROS). In the brain, activated
microglia are a major origin of cytokines and oxidizing
radicals which are produced subsequent to activation of
intracellular peroxidases and oxidative processes [9].
ROS can activate pro-inflammatory pathways and subse-
quently cause to damage of vulnerable neurons. Several
studies showed that both oxidative stress and neuro-
inflammation play a role in the neurodegeneration of
SNc observed in PD [10,11]. The dopaminergic neurons
(DA-neurons) of SNc are highly vulnerable to oxidative
stress due to the high oxygen demand of this brain re-
gion together with the low levels of antioxidant enzymes
[12]. Previous studies have demonstrated increase of ac-
tivated microglia in the SNc of parkinsonian patients [8].
It has been found that microglial activation result in thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[13,14]. Furthermore, the levels of proinflammatory cy-
tokines such as tumor necrosis factor alpha (TNF-α),
interleukin-1beta (IL-1β) and IL-6 that expressed by glial
cells, increased markedly in the serum, brain and cere-
brospinal fluid (CSF) of patients with PD [8,15,16]. To
present, no effective therapies have been developed to
treat PD; however, modulation of neuroinflammation is
important to modify disease progression.
Silymarin (SM), is a polyphenolic flavonoid derived
from the seeds and fruits of the milk thistle plant (Sily-
bum marianum), routinely used to treat liver diseases
and have antioxidative [17], anti-apoptotic [18], anti-
inflammatory [19,20], and neuroprotective properties
[21]. The anti-oxidative activity of SM is due to the scav-
enging of free radicals and activation of superoxide
dismutase [22]. SM inhibits microglia activation and de-
creases inflammatory mediators; the mechanisms by
which it protects dopaminergic neurons from lipopoly-
saccharide induced neurotoxicity [23]. Furthermore, sev-
eral studies demonstrated protective effects of SM in
several experimental models of neuronal injury, particu-
larly in focal cerebral ischemia and cerebral ischemia–re-
perfusion-induced brain injury in rats [24,25]. However,
less information is available about its effect on motor
deficits associated with Parkinson disease. Therefore, the
present study aims to investigate the effect of SM on 6-
hydroxydopamine (6-OHDA)-induced motor imbalance
and modification of cerebral levels of IL-1β and MDA as
indicators of neuro-inflammation and oxidative damage.
Material and methods
Chemicals
All chemicals were purchased from Sigma Chemical Co.
(USA). Solutions were made freshly on the days of ex-
perimentation by dissolving drugs in physiological saline
(0.9% NaCl) except for silymarin which was dissolved in
50% polyethylene glycol (PEG). The drugs were injected
intraperitoneally (i.p.) except for 6-hydroxydopamine (6-
OHDA) which was injected into right substantia nigra
pars compacta (SNc).
Animals
Male Wistar rats (220 ± 20 g) were used in this study.
The animals were given food and water ad libitum and
were housed in standard polypropylene cages, four per
cage at a ambient temperature of 25 ± 2°C under a 12-h
light/12-h dark cycle. Animals were habituated to the
testing conditions including being transferred to the ex-
perimental environment, handled, weighed, and trained
on the test platform for 10 min 2 days before the behav-
ioral investigations were conducted. The present study
was carried out in accordance with the ethical guidelines
for the Care and Use of Laboratory Animals of TabrizUniversity of Medical Sciences, Tabriz, Iran (National In-
stitutes of Health Publication No. 85–23, revised 1985).Experimental protocol
In the beginning of study only the rats that showed nor-
mal walking on rotarod (700 ± 20 sec) were subjected to
further experimentation. The healthy animals were ran-
domized into 8 groups each consisting of eight rats. Rats
in group 1 (control or intact) received no injection and
were left untreated for the entire period of the experi-
ment. Rats in group 2 (sham operated) were injected
with saline containing 0.2% (w/v) ascorbic acid into SNc.
Rats in group 3 received only 6-OHDA (8 μg/2 μl/rat;
intra-SNc). Rats in group 4 pre-treated with vehicle PEG
(i.p.) daily for 5 consecutive days and then were received
intra-SNc injection of 6-OHDA in the same way as
group 3. Rats in group 5 (positive control) pre-treated
with i.p. administration of silymarin 200 mg/kg once
daily (9 a.m.). Rats in groups 6 to 8 pre-treated with i.p.
administration of silymarin (100, 200 and 300 mg/kg)
once daily (9 a.m.) for 5 days and then were received
intra-SNc injection of 6-OHDA in the same way as
group 3 and then, after 3 weeks as recovery period, all
animals were tested by rotarod.
At the end of experiments, the animals were anesthe-
tized by i.p. injection of ketamine (80 mg/kg) and xyla-
zine (10 mg/kg) and their cerebro-spinal fluid (CSF)
were collected (as described below) and prepared for
further analysis of IL-1β. Then animals were euthanized
by an overdose of ether and the striatal tissue samples
prepared for MDA assay.Surgical procedures
The animals were anesthetized by i.p. injection of keta-
mine (80 mg/kg) and xylazine (10 mg/kg). After the rats
were deeply anaesthetized (loss of corneal and toe pad
reflexes), they were fixed in a stereotaxic frame (Stoelting,
Wood Lane, IL, USA) in the flat position. The scalp hairs
were completely shaved, swabbed with povidone iodine
10% and a central incision made to reveal skull. The coor-
dinates for this position were determined according to the
rat brain in stereotaxic coordinates [26] anteroposterior
from bregma (AP) = −5.0 mm, mediolateral from the
midline (ML) = 2.1 mm and dorsoventral from the skull
(DV) = −7.7 mm. Desipramine (25 mg/kg, i.p.) was injected
30 min before intra-nigral injection of 6-OHDA to avoid
degeneration of noradrenergic neurons. Then 6-OHDA
(8 μg/per rat in 2 μl saline with 0.2% ascorbic acid) was
infused by infusion pump at the flow rate of 0.2 μl/min
into the right substantia nigra. At the end of injection,
cannula was kept for an additional 2 min and then slowly
was withdrawn. Sham-operated animals were submitted
to the same procedure except 2 μl vehicle of 6-OHDA
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fused into the SNc.
Cannula verification
For confirmation of placement of the cannula in the
SNc of the brain, at the end of experiments all rats with
guide cannula were euthanized by a high dose of ether
and decapitated. The brains were removed and placed in
a formaldehyde (10%) solution. After 1 week, the tissues
were then embedded in paraffin. Then serial sections
(3 μm) were cut with a microtome (Leitz, Germany),
and as shown in (Figure 1), the placement of the tip of
the cannula in the SNc, AP from bregma = −5.0 mm,
was microscopically controlled (Figure 1). Data from rats
with an incorrect placement of injecting cannula were
excluded from the analysis.
Rotarod assay test
Animals were transferred to the experimental room at
least 1 h before the test in order to let them habituate to
the test environment. Assessment of motor coordination
and balance was done by a commercially available rat
rotarod apparatus on the day of 21 after 6-OHDA injec-
tion (Figure 2). Rat was mounted on the rotarod (18
RPM) and the time latency to fall from the rod was
automatically recorded. All observations were made be-
tween 9 AM and 4 PM by an observer who was blind to
the entity of treatments. All rats were pre-trained for
2 days in order to reach a stable performance. The la-
tency to fall from the apparatus was recorded. MotorRight SNc nuclei region in rat according to paxino
& watson atlas in stereotaxic coordinates  (25)
Place of the tip of cannula in the SNc of the rat 
brain (AP from bregma=-5 mm)
Figure 1 Photomicrograph section of rat brain. Placement of the cannu
coordinates (25). Anteroposterior from bregma (AP) = −5.0 mm. Gomeri’s obalance was assessed three weeks after neurotoxin injec-
tion in four consecutive times, each lasting 720 s (with
one hour interval). Values were expressed as retention
time on the rotarod in the four test trails.
CSF sampling
At the end of experiments, the anesthetized rats were
mounted in a stereotaxic frame. The surface of the neck
region were shaved and swabbed with ethanol (70%).
The position of the animal’s head was sustained down-
ward at almost 45°. A needle (scalp vein-23) which con-
nected to a draw syringe was put horizontally and
centrally into the cisterna magna for CSF collection with
no incision at this region. The colorless CSF sample was
slowly drawn into the syringe in a volume of 100 μl. The
CSF samples were kept frozen at −70°C until assessment
by enzyme-linked immunosorbent assay (ELISA) method.
Malondialdehyde (MDA) assay
For MDA assessment, rats (n = 8) were euthanized, and
selected brain regions (midbrain) were rapidly removed,
cleaned, and immediately frozen in liquid nitrogen. Sub-
sequently, tissue samples were weighed and homoge-
nized (IKA Homogenizer, Staufen, Germany) in ice-cold
buffer phosphate (50 mM, pH 6.0 at 4-8°C) and then
were centrifuged at 10000 rpm for 20 min at 4°C. The
supernatant was aliquot and stored at −80°C for further
analysis. The MDA concentration in the supernatant
was measured as described before [27]. Briefly, tri-
chloroacetic acid and TBARS reagent were added tos
la is shown according to the paxinos & Watson atlas in stereotaxic
ne-step Trichrom method (10 M).
sampling
6-OHDA
(intra-SNc)SM or vehicle (ip) Rotarod test





Figure 2 Schematic representation of the experimental procedure; see text for details.
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80 min. After cooling on ice, samples were centrifuged
at 1000 × g for 20 min and the absorbance of the super-
natant was read at 532 nm. TBARS results were
expressed as MDA equivalents using tetraethoxypropane
as standard. The protein content of the supernatant was
measured using Bradford Protein Assay kit (Sigma
Chemical, St. Louis, MO).
IL-1β assay
The CSF level of IL-1β was determined by using com-
mercial ELISA kits (Rat IL-1β kits, IBL, Hamburg,
Germany) according to the manufacture’s instruction.
Conditions were the same for all assays. Briefly, the frozen
CSF samples were diluted, added into the wells and incu-
bated at room temperature for 120 min on a microplate
shaker. After washing, diluted Streptavidin-Horseradish
peroxidase-conjugated anti-mouse IL-1β was reacted for
60 min at room temperature (on microplate shaker set at
200 rpm). After washing again, the wells were developed
with tetramethyl benzidine (TMB) for 10 min and the op-

























Figure 3 The rotarod results of normal, sham-operated and 6-OHDA-
elapsed time on the rod (s); n = 8 rats for each group; ≠p < 0.001 as compaThe concentration of the IL-1β was expressed as pg/ml
of CSF.
Statistical analysis
Data were expressed as the mean ± SEM, and were ana-
lyzed by one-way ANOVA in each experiment. In the
case of significant variation (p < 0.05), the values were
compared by Tukey test.
Results
The effect of intra-SNc-injection of 6-OHDA on
motor- balance
The effect of intra-SNc injection of 6-OHDA on motor-
coordination was evaluated by rotarod test. The duration
of time to fall from rotating rod was evaluated in three
groups of rats: normal, sham operated and 6-OHDA
(8 μg/2 μl/rat)-lesioned rats. Drugs and vehicle were
injected into the SNc through the implanted guide can-
nula. As shown in Figure 3, 6-OHDA was able to induce
significant (p < 0.001) motor imbalance in comparison
with both normal and sham-operated rats so that 6-









lesioned (8 μg/2 μl/rat) rats. Each bar represents the mean ± SEM of
red with normal and sham-operated groups. (L = .Lesioned).
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with normal group) in retention time on rotarod was ob-
served in these animals (Figure 3).
Effect of silymarin on 6-OHDA induced motor-incoordination
The effect of pre-treatment with silymarin (100, 200 and
300 mg/kg, i.p.) and its vehicle for 5 days, on 6-OHDA
induced motor-incoordination was assessed 3 weeks
after injection of 6-OHDA. In these groups motor bal-
ance was tested on 21 days after surgery for 4 repeated
times (5, 60, 120 and 180 min). The results indicated



































































Figure 4 The rotarod test results of 6-OHDA (8 μg/2 μl/rat)-lesioned r
for 5 days) (A) and silymarin vehicle (B). Each bar represents the mean ±
†p <0.001 between normal and 6-OHDA groups; ***p < 0.001 when compa
normal rats. (SM = Silymarin); (V = Vehicle of silymarin); (L = .Lesioned).improved motor balance in 6-OHDA lesioned rats in a
dose dependent manner (Figure 4A) so that the latency
time to fall off increased (198%, 287% and 304%) in le-
sioned rats pre-treated with 100, 200 and 300 mg/kg of
SM with respect to rats treated with vehicle, respectively.
No alteration was observed on rotarod elapsed time in
vehicle pre-treated rats (Figure 4B).
Effects of 6-OHDA and silymarin on the brain level of MDA
To investigate the possible involvement of MDA as a
marker of the oxidative stress in PD we appraised the

























ats that pre-treated with silymarin (100, 200 and 300 mg/kg, i.p.
SEM of elapsed time (s) on the rod; n = 8 rats for each group;
red with 6-OHDA lesioned rats; ‡p < 0.001 when compared with
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study 6-OHDA injection given to the rats resulted in a sig-
nificant (p < 0.001 vs. control) increase in lipid peroxida-
tion in brain tissue, as measured by an increase in the
level of MDA in the brain (Figure 5). The MDA level in
the brain was found to reduce from 11.4 ± 1.1 nm/mg
protein in 6-OHDA group to 6.62 ± 0.51, 6.25 ± 0.48 and
5.6 ± 0.63 (p < 0.001) nm/mg pr., in SM (100, 200, and
300 mg/kg/day) pre-treated groups, in a dose dependent
manner, respectively (Figure 5).
Effect of silymarin on the CSF level of IL-1β
To further explore on the protection against 6-OHDA
induced Parkinson disease by silymarin, the potential ef-
fect of silymarin on the level of IL-1β, which is a key
pro-inflammatory cytokine released following microglia
activation, was investigated in the present study. The re-
sults showed that 6-OHDA markedly increased the IL-1β
level by 286.5% (P < 0.001 vs. control) (Figure 6). Pre-
treatment with silymarin with all three doses (100, 200,
and 300 mg/kg/day) significantly attenuated the level of
IL-1β from 332.8 ± 52 pg/ml of CSF in the 6-OHDA
group to 129.5 ± 26 (P < 0.001), 113.2 ± 11 (P < 0.001), and
86.16 ± 7 (P < 0.001) pg/ml respectively, in a dose-dependent
manner (Figure 6).
Discussion
We have previously reported that short-term administra-
tion of silymarin at induction of PD by 6-OHDA
prevents from catalepsy and reduces myeloperoxidase
activity and inflammatory cytokines [28]. In the present
study it has been indicated that SM improves motor im-
pairment following intra-SNc injection of 6-OHDA in
rats and amends the neuroinflammation and oxidative
stress factors.Figure 5 The effect of i.p. administration of silymarin (SM) at the doses
in midbrain as measured by MDA concentration. Values are mean ± SEM
with 6-OHDA injected group using one way ANOVA with Tukey post hoc tesDifferent beneficial effects of silymarin have been re-
ported in several in vitro and in vivo studies. Recently,
the beneficial effect of silymarin has been reported in an
Alzheimer’s disease rat model [29]. However, less infor-
mation is available about its effect on motor impairment
in experimental models of PD. Behavioral assessment is
a strong hallmark in evaluation of neuroprotection. Par-
ticularly, in rodents, motor-incoordination which is a re-
liable marker of the nigrostriatal neurodegeneration, is
one symptoms of PD that can be created by unilateral
intra-SNc injection of 6-OHDA and assessed by rotarod
as a common standard motor-balance test [30]. In the 6-
OHDA-induced PD model used in the present study, 6-
OHDA caused a significant motor-imbalance, so that
walking of rats on the rotating drum was lesser in 6-
OHDA lesioned group compared to the control group.
This is in accordance to previous studies reported that
6-OHDA (8-12 μg/2 μl/rat) induces motor-imbalance as
an early symptom of PD by decreasing number of SNc
neurons [30,31]. Indeed unilateral lesion of SNc compels
a rat to put its weight abnormally on the both sides of
its body for movement and equilibrium; hence this cause
to motor disorders and motor asymmetry [31,32].
According to the results, silymarin (in all three doses)
improved motor-incoordination induced by 6-OHDA.
Baluchnejadmojarad et al. reported that silymarin atten-
uates the rotational behavior in 6-OHDA-lesioned rats
and protects nigrostriatal neurons against 6-OHDA-
induced neurodegenerative process [21]. 6-OHDA has
pro-oxidant activity which causes to neurotoxicity. This
toxin subsequent of auto-oxidation in the extracellular
space, produce reactive oxygen species (ROS) [33]. Fur-
thermore, it has been reported that 6-OHDA induce DA
cells degeneration selectively by generation of free radi-
cals and subsequently induction of oxidative stress andof 100, 200, and 300 mg/kg/day (for 5 days) on lipid peroxidation
(n = 8). †P < 0.001 from respective normal value; ***P < 0.001 as compared
t. (L = .Lesioned).
Figure 6 The effect of i.p. administration of silymarin (SM) at the doses of 100, 200, and 300 mg/kg/day (for 5 days) on IL-1β concentration
in CSF (Figure 6). Values are mean ± SEM (n = 8). †P < 0.001 from respective normal value; ***P < 0.001 as compared with 6-OHDA injected group
using one way ANOVA with Tukey post hoc test. (L = .Lesioned).
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oxidative stress result in microglia activation which leads
to neurotoxicity of DA-neuron [14]. We suggest that the
observed enhancement of motor balance in silymarin
pre-treated hemi-parkinsonian rats in this study may be
due to its possible neuroprotective effect. This effect
may be exerted through counteracting oxidative stress
process [35] maybe through regulating antioxidant
defense system as well as inhibition of free radical gener-
ation [35].
To investigation of this issue, we also evaluated brain
levels of MDA as lipid peroxidation marker in silymarin
pre-treated hemi-parkinsonian rats. Malondialdehyde, a
thiobarbiturate reactive substance, which formed as an
end product of the peroxidation of lipids, served as an
index of the intensity of oxidative stress. Our result
showed a marked increase in midbrain lipid peroxidation
as evidenced by elevation of MDA concentration in 6-
OHDA-lesioned rats whereas, silymarin prevented dose-
dependently from increase of MDA levels and restored
it to the range of intact animals. According to these
finding, we thought that silymarin attenuates the sever-
ity of oxidative stress through inhibition of lipid peroxi-
dation. Also, it has been reported that the level of brain
superoxide dismutase (SOD) and glutathione reductase
(GR) as antioxidant enzymes decreased in parkinsonian
rats and SM restored their levels in parkinsonian ani-
mals [21,36], which are totally in agreement with our
findings.
Another key finding of the present study was that the
reduction of brain MDA levels in silymarin pre-treated
parkinsonian rats was associated with a significant de-
crease in pro-inflammatory cytokine. Our results showed
that hemi-parkinsonian rats have a significant increase
in CSF level of IL-1β, whereas its level was restored up
to the normal range of intact animals by silymarin. Thisis in accordance with other previous studies which show
that 6-OHDA- neurotoxicity induced by microglia acti-
vation and subsequent increase of TNF-α, IL-6 and IL-
1β levels in both substantia nigra (SN) and striatum
[8,37-39]. DA neurons in SNc are vulnerable to inflam-
matory affront as a major exciter of neurodegenerative
disease because of high density of microglia in SNc [40].
Pro-inflammatory cytokines such as TNF-α, IL-6 and IL-
1β are released by activated microglia in striatum and
SN [41], which have an important role in neurotoxicity
[42]. It was noted that SM reduced the levels of IL-6 and
TNF-α as well as suppression of MPO activity in hemi-
parkinsonian rats [28]. Furthermore silymarin inhibit
nuclear factor kappa B (NF-kB) activation in DA neu-
rons [23], and down-regulate cyclooxygenase-2 (COX-2)
in brain [25], which could subsequently decrease release
of IL-1β.
The anti-oxidant activity can be considered as a pos-
sible neuroprotective mechanism of silymarin in PD. It
can be postulated that neuroprotective and anti-neuro-
inflammatory effects of silymarin, in 6-OHDA induced
hemi-parkinsonian rats, are almost due to reduction of
pro-inflammatory cytokines and suppression of oxidative
stress.
Conclusion
In conclusion, we found that short-term pre-treatment
with silymarin improved 6-OHDA-induced motor-
imbalance and protected animals against neurotoxicity
of 6-OHDA. Furthermore silymarin decreased CSF levels
of IL-1β and decreased lipid peroxidation as evidenced
by striatal level of MDA in 6-OHDA-lesioned rats. We
suggest a possible protective role for SM against neuro-
inflammation and oxidative damages induced in PD.
More clinical investigations should be done to prove its
therapeutical application in PD.
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